Clinical trial
Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute…
NCT00003991 · Maxim Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00003991 |
|---|---|
| Title | Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia |
| Official title | Multi-Center, Randomized Open-Label Study to Evaluate the Safety and Efficacy of Immunotherapy With Subcutaneous Maxamine (Histamine Dihydrochloride) Plus Proleukin (Interleukin-2) Versus No Treatment (Standard of Care) in Patients With Acute Myeloid Leukemia in First or Subsequent Complete… |
| Lead sponsor | Maxim Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | aldesleukin, histamine dihydrochloride |
| Enrollment | 360 |
| Start date | Jul 1, 1998 |
| Completion | Aug 1, 2011 |
| First posted | Jun 3, 2004 |
| Last update posted | Nov 6, 2013 |
| Countries | Australia, Canada, Denmark, Estonia, Finland, France, Germany, Israel, New Zealand, Sweden, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: